首页|University of British Columbia Reports Findings in Machine Learning (Predictive modelling of Immunogenicity to Botulinumtoxin A Treatments for Glabellar Lines)
University of British Columbia Reports Findings in Machine Learning (Predictive modelling of Immunogenicity to Botulinumtoxin A Treatments for Glabellar Lines)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News-New research on Machine Learning is th e subject of a report. According to news reporting originating from Vancouver, C anada, by NewsRx correspondents, research stated, "Botulinum toxin A (BoNT-A), d erived from Clostridium botulinum, is widely used in medical and aesthetic treat ments. Its clinical application extends from managing chronic conditions like ce rvical dystonia and migraine to reducing facial wrinkles." Our news editors obtained a quote from the research from the University of Briti sh Columbia, "Despite its efficacy, a significant chAllenge associated with BoNT -A therapy is immunogenicity, where the immune system produces neutralising anti bodies (NAbs) against BoNT-A, reducing its effectiveness over time. This issue i s critical for patients requiring repeated treatments. The study aims to compare FDA-approved BoNT-A products, examining the factors influencing NAbs developmen t using advanced machine learning techniques. This research analysed data from r andomised controlled trials (RCTs) involving five main BoNT-A products. The stud y selected trials based on detailed immunogenic responses to these treatments, p articularly for glabellar lines. Machine learning models, including logistic reg ression, random forest classifiers, and Bayesian logistic regression, were emplo yed to assess how treatment specifics and BoNT-A product types affect the develo pment of NAbs. Analysis of 14 studies with 8,190 participants revealed that dosa ge and treatment frequency are key factors influencing the risk of NAbs developm ent. Among BoNT-A products, IncobotulinumtoxinA shows the lowest, and Abobotulin umtoxinA the highest likelihood of inducing NAbs. The study's machine learning a nd logistic regression findings indicated that treatment planning must consider these variables to minimise immunogenicity. The study underscores the importance of understanding BoNT-A immunogenicity in clinical practice. By identifying the main predictors of NAbs development and differentiating the immunogenic potenti al of BoNT-A products, the research provides insights for clinicians in optimisi ng treatment strategies."
VancouverCanadaNorth and Central Ame ricaCyborgsEmerging TechnologiesMachine Learning
NETL
NSTL
